Document:

Exhibit 10.36

Exhibit 10.36

EXECUTION VERSION

AMENDED AND RESTATED LICENSE AGREEMENT

THIS AMENDED AND RESTATED LICENSE AGREEMENT (“Agreement”) is made and entered into effective
as of July 2, 2008 (the “Amendment Effective Date”), by and between ONCOGENEX TECHNOLOGIES INC.,
having offices at #400 — 1001 West Broadway, Vancouver, B.C. V6H 4B1 (“OncoGenex”) and ISIS
PHARMACEUTICALS, INC., having principal offices at 1896 Rutherford Road, Carlsbad CA 92008-7208
(“Isis”). OncoGenex and Isis each may be referred to herein individually as a “Party,” or
collectively as the “Parties.”

WHEREAS, the Parties entered into a Collaboration and Co-Development Agreement dated November
16, 2001 (the “Original Collaboration Agreement”) which collaboration resulted in the development
of OGX-011, a second generation antisense inhibitor of Clusterin;

AND WHEREAS, the Parties now wish for OncoGenex to proceed with unilateral development of
OGX-011 and Products and in this connection wish to enter into this Agreement to amend and restate
the Original Collaboration Agreement, as provided herein.

NOW, THEREFORE, the Parties do hereby agree as follows:

ARTICLE 1

DEFINITIONS

Capitalized terms used in this Agreement and not otherwise defined herein have the meanings
set forth in Appendix A.

ARTICLE 2

TERMINATION OF COLLABORATION

Section 2.1 Previous Collaboration. Pursuant to the Original Collaboration Agreement, commencing
November 16, 2001 the Parties collaborated to jointly develop OGX-011 and the Products to the
present stage of development (the “Collaboration”). As of the Amendment Effective Date, the
Collaboration is terminated.

ARTICLE 3

CESSATION OF OPERATION OF COLLABORATION

Section 3.1 Dissolution of Operating Committee. Pursuant to Article 3 of the Original
Collaboration Agreement, the Parties established an “Operating Committee” to oversee the
Collaboration. As of the Amendment Effective Date, the Operating Committee is hereby dissolved and
the Operating Committee will have no further responsibility, authority or function.

 

	 	 	 
	*	 	Certain information in this exhibit has been omitted as confidential, as indicated by [***]. This
information has been filed separately with the Commission.

 

 

 

ARTICLE 4

LICENSE GRANT, TECHNOLOGY TRANSFER, DILIGENCE

Section 4.1 License Grant.

4.1.1 Nonexclusive License. Subject to the terms and conditions of this Agreement, Isis
hereby grants to OncoGenex a worldwide, nonexclusive license, with the right to grant sublicenses
as set forth in Section 4.1.2 below, under the Isis Core Technology, Isis Core Technology Patents,
Isis Manufacturing Technology and Isis Manufacturing Patents to research, develop, make, have made,
use, gain regulatory approval, commercialize, sell, offer for sale, have sold, export and import
OGX-011 and Products for all uses.

4.1.2 Sublicenses. The licenses granted to OncoGenex under this Article 4 are sublicensable
only in connection with a license of OGX-011 or a Product to any Affiliate of OncoGenex or to any
Third Party, in each case for the continued Development and Commercialization of OGX-011 or such
Product in accordance with the terms of this Agreement, provided that (i) such Affiliate or Third
Party will agree in writing to be bound by and subject to all applicable terms and conditions of
this Agreement in the same manner and to the same extent as OncoGenex, and (ii) OncoGenex will
remain responsible for the performance of this Agreement and will cause such Affiliate or Third
Party to comply with the applicable terms and conditions of this Agreement. In addition to the
requirements and limitations set forth above, with respect to the Isis Manufacturing Technology,
OncoGenex will (a) name Isis as a third party beneficiary with the right to directly enforce
Article 7 (Confidentiality) of this Agreement against such Affiliate or Third Party, (b) promptly
notify Isis in writing specifically identifying the Isis Manufacturing Technology to be disclosed
to such Third Party and identifying by name such Third Party and (c) use appropriate precautions
and include provisions in such sublicense to protect the Isis Manufacturing Technology such that
the sublicensee will not use any Isis Manufacturing Technology to manufacture any other ASOs for
Third Parties and in any event OncoGenex will not provide to any Third Party manufacturer any batch
record transferred by Isis to OncoGenex under this Agreement.

4.1.3 Follow On/Back-up Compounds. At OncoGenex’ request, Isis and OncoGenex will negotiate
in good faith a reasonable research plan and corresponding budget, at the same FTE rate as set
forth in the Original Collaboration Agreement, to identify exclusively for OncoGenex additional MOE
Gapmers that modulate Clusterin (“Follow-on Compounds”). In such event and after OncoGenex has
paid Isis pursuant to such research plan, the definition of “Product” under this Agreement shall
include the Follow-on Compounds.

4.1.4 Improvements. To the extent that Isis has the right to license an Improvement, the
Parties will negotiate in good faith regarding the use of any such Improvement to research,
develop, make, have made, use, gain regulatory approval, commercialize, sell, offer for sale, have
sold, export and import OGX-011 and Products for all uses. If OncoGenex gives to Isis written
notice of its desire to obtain a license to an Improvement, the Parties shall negotiate in good
faith and attempt to reach mutual agreement upon a commercially reasonable agreement under which
OncoGenex obtains a license under such Improvement, and all patent and other
intellectual property rights therein and thereto, to research, develop, make, have made, use,
sell, offer for sale, have sold and import Products. The license will be sublicensable in
accordance with Section 4.1.2. If requested by OncoGenex, Isis will give to OncoGenex a written
description of such Improvement in reasonably specific detail, together with such data and
information as reasonably requested by OncoGenex.

 

2

 

4.1.5 Exclusivity. Subject to Section 12.2.2, neither Isis nor any of its Affiliates will
(a) engage, on behalf of itself or for any other party, in the research, development, manufacture,
production, release or commercialization of ASOs that act predominantly by [***] Clusterin [***] or
that are [***] Clusterin [***] or products containing such ASOs, or (b) grant to any other party
any license, immunity or other right, in each case other than a Permitted License or as otherwise
set forth on Appendix F, to do any of the foregoing. Isis represents and warrants that all
Permitted Licenses as of the Amendment Effective Date are listed on Appendix F.

4.1.6 [***] and [***] Patents. Without limiting OncoGenex’ obligations under Section 6.2.4,
Isis will timely pay in full all amounts required to be paid by Isis, and timely perform in full
all obligations required to be performed by Isis, under the [***] Agreement and the [***]
Agreement. Without the prior express written consent of OncoGenex (such consent not to be
unreasonably withheld, conditioned or delayed), Isis will not (and will take no action or make no
omission to) modify or waive any material provision of the [***] Agreement or the [***] Agreement
that could impair the value of the sublicenses granted to OncoGenex under the [***] Agreement or
the [***] Agreement, or to terminate or have terminated the [***] Agreement or the [***] Agreement.

Section 4.2 Assignment, Technology Transfer.

4.2.1 Assignment. Isis previously has assigned and transferred, or will assign and transfer,
and hereby does assign and transfer, to OncoGenex or its designee, all rights, title, and interests
in and to the Product-Specific Technology and the Product-Specific Technology Patents.
Simultaneously with the execution of this Agreement, Isis will execute and deliver a confirmatory
assignment relating to all Product-Specific Technology Patents listed on Appendix G.

4.2.2 Isis Transfer of Technology. Subject to the terms and conditions of this Agreement, Isis
will transfer to OncoGenex, or a Third Party designate selected solely by OncoGenex, (a) all
know-how required to use and interpret the Release Methods, (b) all software necessary for the
conduct of the Release Methods, (c) the Supply Chain Network necessary for the manufacture of the
Product, (d) any Isis Core Technology, (e) any Product-Specific Technology and (f) the Isis
Manufacturing Technology, in each case Controlled by Isis on the Amendment Effective Date. Isis
will use Commercially Reasonable Efforts to complete such transfer pursuant to this Section 4.2.1
within 120 days following the Amendment Effective Date. If (i) such transfer requires more than
[***] (ii) such transfer is made to a Third Party manufacturer, or (iii) OncoGenex reasonably
requests further technical assistance with respect thereto, then, in each case, OncoGenex will pay
to Isis the standard Isis FTE rate for the time to complete such transfer or to provide such
assistance. Any transfer made under this Section 4.2.1 is subject to Section 4.1.2 and Article 7.

 

3

 

4.2.3 Transfer of Records. Isis will provide to OncoGenex promptly following OncoGenex’
written request, (a) all batch records related to any Product, including but not limited to
corresponding release data, (b) toxicity and pharmacokinetic data and reports related to such
Product, (c) pharmacology data and reports related to such Product, (d) Product and OGX-011
characterization data, (e) Product and OGX-011 stability data, (f) any other records, including,
but not limited to, raw data or interim or final reports, related to such Product or OGX-011, and
(g) all Regulatory Documents, in each case that are in the possession of Isis or its Affiliates, or
any third party engaged by Isis or any of its Affiliates. OncoGenex will promptly share with Isis
a summary of the data and results related to each clinical trial conducted by OncoGenex that was
completed or commenced prior to the Amendment Effective Date in substantially the form, and with
substantially the content, of OncoGenex’ regular reports provided to its board of directors
regarding such clinical trial, but in any event by the later of (i) 60 days following the Amendment
Effective Date and (ii) the date OncoGenex comes into possession of such information.

Section 4.3 Supply of Existing OGX-011. Isis will supply OncoGenex, and OncoGenex will purchase
from Isis, the [***] grams of OGX-011 API in Isis’ possession as of the Amendment Effective Date
for a purchase price of $1,356,000, in accordance with the terms and conditions of Purchase Order
No. 184, dated February 14, 2006, issued by OncoGenex to Isis (including without limitation the
specifications, warranties and other obligations set forth in the Terms and Conditions of Purchase
attached thereto, other than the purchase price and payment terms), with the same effect, and to
the same extent, as if such supply and purchase had been made pursuant to such Purchase Order. In
connection therewith, Isis shall deliver to OncoGenex an updated Certificate of Analysis dated not
more than ninety (90) days prior to the date of delivery to OncoGenex. OncoGenex acknowledges and
agrees that in order to perform the testing necessary to provide the updated certificate of
analyses, Isis will need to use approximately [***] grams of such API. Within ninety (90) days
following the receipt by OncoGenex of such API and such Certificate of Analysis, each provided in
accordance herewith, OncoGenex shall pay to Isis the purchase price set forth in this Section 4.3
and take delivery of the API purchased by OncoGenex hereunder plus approximately [***] grams of API
previously purchased by OncoGenex.

Section 4.4 Diligence. OncoGenex will use Commercially Reasonable Efforts to develop and
commercialize OGX-011 and Products.

ARTICLE 5

DEVELOPMENT & COMMERCIALIZATION

Section 5.1 Development, Commercialization and Regulatory Responsibilities. OncoGenex will have
sole responsibility, including without limitation sole responsibility for all funding, resourcing
and decision making, for all further development and commercialization with respect to OGX-011 and
Products. OncoGenex hereby assumes all regulatory responsibilities in connection with OGX-011 and
Products, including sole responsibility for all Regulatory Documents and for obtaining all
regulatory approvals. OncoGenex will comply with all Applicable Laws in connection with the
development and commercialization of OGX-011 and Products. All INDs, NDAs, MAAs and other
regulatory filings for OGX-011 and Products will be owned by OncoGenex.

 

4

 

Section 5.2 Reports by OncoGenex. At Isis’ request, after the first anniversary of the Amendment
Effective Date, OncoGenex will provide an annual report to Isis summarizing OncoGenex’ development
and commercialization activities over the past year regarding the Product in substantially the
form, and with substantially the content, of OncoGenex’ regular reports provided to its board of
directors regarding the Product. In addition, OncoGenex will promptly respond to any reasonable
follow-up questions Isis may have regarding such reports solely to the extent necessary to
determine whether OncoGenex is in compliance with its obligations to use Commercially Reasonable
Efforts under Section 4.4. Isis shall have the right to use such reports solely to reasonably
determine whether OncoGenex is in compliance with its obligations to use Commercially Reasonable
Efforts under Section 4.4.

Section 5.3 Safety Database. Isis maintains a database that includes information regarding the
safety and tolerability of its drug compounds, individually and as a class, including information
discovered during pre-clinical and clinical development (the “Isis Database”).

5.3.1 To the extent OncoGenex and its Affiliates have collected data and information
specifically regarding Products, and subject to Applicable Law, including, without limitation, all
applicable privacy laws, rules and regulations (such as the Health Insurance Portability
Accountability Act), any applicable informed consents, and any obligations or restrictions imposed
by Third Party clinical sites relating to dissemination or use of such data and information, in an
effort to maximize understanding of the safety profile and pharmacokinetics of Isis compounds,
OncoGenex will provide Isis with the following: (a) copies of [***] and [***] summary reports, and
[***] final reports, in each case specifically regarding Products, and (b) in connection with any
reported [***] (including any follow-up or amended reports) specifically regarding a Product, the
following [***] regarding the applicable Product: (i) [***]; (ii) [***] usage; (iii) particulars of
[***]; (iv) [***] history [***]; and (v) [***]. All such data and information disclosed by
OncoGenex to Isis in connection with this Section 5.3, together with any data and information
related to the [***] of each Product and any [***], will be OncoGenex’ Confidential Information.
Isis shall use such Confidential Information solely for the purpose of populating the Isis
Database, and for no other purpose. Isis shall not disclose any such Confidential Information to
any Third Party; provided, however, that Isis may conduct analyses to keep Isis and its partners
informed regarding class generic safety and pharmacokinetic properties of ASOs so long as Isis does
not disclose to such Third Parties the identity of the applicable Product, Clusterin as the target,
OncoGenex or its Affiliates (or any information that would foreseeably reveal the identity of the
applicable Product, Clusterin as the gene target, OncoGenex or its Affiliates) or any patient
identifying information.

5.3.2 To the extent that [***] OncoGenex under this Agreement collects safety and tolerability
data or information specifically regarding a Product, OncoGenex shall use commercially reasonable
efforts to obtain from such sublicensee (a) the right to provide to Isis (whether through OncoGenex
or its Affiliate, or directly from such sublicensee) the [***] described in [***] and (b) the right
of Isis to [***] for the purposes described in [***]. Only sublicensees that agree to provide such
[***] and grant Isis the right to use such [***] as set forth herein, will have the right to access
the results of any queries requested by OncoGenex. If and when Isis identifies safety,
pharmacokinetic or other related issues that may be relevant to a Product [***] Isis will promptly
inform OncoGenex of such issues, and if requested, provide the data and information supporting
Isis’ conclusions regarding such issues. In addition, at
OncoGenex’ reasonable request and at no cost to OncoGenex, Isis will [***] the Isis Database
to provide OncoGenex information regarding [***] or other related issues.

 

5

 

5.3.3 To the extent OncoGenex or its Affiliate obtains safety and tolerability data or
information specifically regarding a Product, and such data or information is subject to any
restrictions or obligations imposed by a Third Party clinical site, OncoGenex shall use
commercially reasonable efforts to obtain from such Third Party clinical site (a) the right to
provide to Isis the data and information described in this Section 5.3, and (b) the right of Isis
to use such data and information for the purposes described in this Section 5.3.

ARTICLE 6

FINANCIAL PROVISIONS

Section 6.1 Initial Payment by OncoGenex. The Parties acknowledge and agree that OncoGenex paid to
Isis $500,000 (U.S.) under section 5.1 of the Original Collaboration Agreement.

Section 6.2 Royalty Payments by OncoGenex; Royalty Term.

6.2.1 Royalty Rate. In consideration of Isis’ collaborative efforts under the Original
Collaboration Agreement and the licenses and assignments granted hereunder, OncoGenex will pay Isis
a base royalty of [***]% of the Net Sales of a Product. In addition, OncoGenex will pay Isis
[***]% of Royalty Revenue in excess of [***]% of Net Sales of Third Parties to a maximum additional
royalty payable to Isis of [***]% of Net Sales of Third Parties.

6.2.2 [***]. Notwithstanding anything to the contrary in this Agreement, if (i) OncoGenex has
an agreement with a Third Party for the further development or commercialization of a Product
pursuant to which such Third Party is selling the Product (a “Commercialization Agreement”),
(ii) under such Commercialization Agreement the [***] by such Third Party to OncoGenex [***] of
such Product under such Commercialization Agreement [***] and (iii) a [***] in any country would
not be infringed by the making, using or selling of a Product in such country by an unauthorized
party, then with respect to such Product in such country, (a) the applicable [***]% base royalty
rate, and the [***]% threshold for and [***]% cap on the additional royalty, under Section 6.2.1
above shall be [***] as such [***] and (b) the aggregate royalty owing to Isis shall not exceed
[***] of the Royalty Revenue retained by OncoGenex.

6.2.3 [***].

(a) Notwithstanding anything to the contrary in this Agreement, subject to Section 6.2.3(c),
if (i) OncoGenex has a Commercialization Agreement, and (ii) under such Commercialization Agreement
the [***] to OncoGenex on the [***] under such agreement because [***] then with respect to such
Product, the applicable [***]% royalty rate, and the [***]% threshold and the [***] on the
additional royalty under Section 6.2.1 above shall be reduced in the same manner and in the same
proportion as such [***].

 

6

 

(b) Notwithstanding anything to the contrary in this Agreement, subject to Section 6.2.3(c) if
(i) OncoGenex does not have a Commercialization Agreement, and (ii) in any
quarter, there are one or more [***] OncoGenex may [***] above on a country-by-country and
Product-by-Product basis by [***] represents of the [***] in such country as reported by IMS plus
(b) [***] in such country, in each case in such quarter. By way of example, if in any quarter the
[***] in a country represents 50% of the [***] of the Product plus all [***] OncoGenex may reduce
the royalties due to Isis under Section 6.2.1 by [***] in such country. Nothing in this
Section 6.2.3 shall modify the obligations of OncoGenex under [***] required pursuant to the [***]
Agreement and the [***] Agreement.

(c) This Section will not apply to [***] by Isis or a Third Party in a country under a license
granted by Isis pursuant to Section 12.2.2, unless a Valid Claim within the Product-Specific
Technology Patents, Isis Core Technology Patents, Isis Manufacturing Patents or Joint Patents in
such country would not be infringed by the making, using or selling of such Product in such country
by an unauthorized party.

6.2.4 Third Party Payments. In addition to the royalty set forth in Section 6.2.1, OncoGenex
will pay to Isis (i) a royalty of [***]% of Net Sales of such Product to the extent required
pursuant to the [***] Agreement; and (ii) a royalty of [***]% of Net Sales of such Product to the
extent required pursuant to the [***] Agreement. In the event that Isis negotiates a reduction or
elimination of the royalties with [***] or [***] following the Amendment Effective Date, the
royalties due under the referenced license agreements will still be paid to Isis.

6.2.5 Noncumulative Relief. If the conditions described in Sections 6.2.2 and 6.2.3 have been
met such that, under both provisions, OncoGenex would be entitled to [***] OncoGenex may [***] by
applying the greater of the [***] such that under no circumstances will Sections 6.2.2 and 6.2.3
work together to cumulatively [***].

Section 6.3 Royalty Term. Royalties payable under Section 6.2 will be payable for each Product on
a country-by-country basis from the first commercial sale of a Product in such country until the
date that is the later of (i) [***] after the first commercial sale of a Product in such country or
(ii) the expiration of the last to expire Valid Claim within the Product-Specific Technology
Patents, Isis Core Technology Patents, Isis Manufacturing Technology or Joint Patents which would
be infringed by the making, using or selling of the applicable Product in the applicable country by
an unauthorized party.

 

7

 

Section 6.4 Timing of Royalty Payments; Preliminary Report.

6.4.1 The royalties calculated in Sections 6.2 or 6.3 will become due and payable within 40
days after each respective Royalty Due Date and will be calculated in respect of the Net Sales in
the calendar quarter period ending with the applicable Royalty Due Date; provided, however, that if
the royalties are adjusted in accordance with Section 6.2.3, then such royalties will become due
and payable within the later of (a) forty (40) days after each respective Royalty Due Date, and
(b) fifteen (15) days after the applicable IMS data is available for the applicable quarter as
necessary to fully calculate the royalty reduction under Section 6.2.3. Furthermore, OncoGenex
agrees to supply Isis the information Isis reasonably requires to comply with any third party
payments under Section 6.3. In the event the applicable IMS data is no longer available, the
Parties agree to negotiate in good faith a reasonable, mutually-acceptable data source to be used
in place of IMS data for purposes of calculating the royalty reduction under
Section 6.2.3. In the event the applicable IMS data (or other reasonable, mutually-acceptable
data described above) is only available on a date that is significantly later than forty (40) days
after the respective Royalty Due Date, the Parties agree to negotiate in good faith a reasonable,
mutually-acceptable mechanism providing for the payment by OncoGenex, within forty (40) days after
the respective Royalty Due Date, of the estimated royalty payment for a quarter based on
commercially reasonable assumptions, and the prompt true-up (in the form of an additional payment,
repayment or credit, as applicable) of such estimated payment once the actual royalty payment for
such quarter may be calculated.

6.4.2 In addition, during the Term following the first commercial sale of any Product, within
10 Business Days after the Royalty Due Date, OncoGenex will provide Isis a preliminary non-binding
quarterly royalty report estimating the total Net Sales of Product and royalty payable for such
calendar quarter. Unless required by applicable law or OncoGenex has already publicly disclosed
such information, Isis shall not directly or indirectly in any manner whatsoever, publicly disclose
the information contained in the preliminary royalty report estimate without first confirming such
information against the payment made by OncoGenex under Section 6.4.1 above for the applicable
period, and without expressly acknowledging that such information is a preliminary non-binding
estimate only. Notwithstanding anything to the contrary in this Agreement, (a) any breach by Isis
of its obligations under Section 6.4.2 shall constitute a material breach under this Agreement, and
(b) OncoGenex will not be liable to Isis for any Loss Isis may suffer as a result of Isis publicly
disclosing information contained in such a preliminary non-binding quarterly royalty report
estimate.

 

8

 

Section 6.5 Non-Royalty Revenue Payments by OncoGenex. Non-Royalty Revenue will be allocated
between the Parties based on the timing of when OncoGenex signs a sublicensing agreement with a
Third Party for the Product as follows:

	 	 	 	 	 	 	 	 	 
	Timing of signing a	 	Isis share of	 	 	OncoGenex share of	 
	sublicensing agreement	 	Non-Royalty Revenue	 	 	Non-Royalty Revenue	 
	 
	 	 	 	 	 	 	 	 
	(a) Prior to the
initiation (i.e.
first patient dosed)
of a first
Registration Clinical
Trial for a Product
	 	 	30	%	 	 	70	%
	 
	 	 	 	 	 	 	 	 
	(b) After (a) but
prior to enrolling
20% of the planned
patients in the first
Registration Clinical
Trial for a Product
	 	 	25	%	 	 	75	%
	 
	 	 	 	 	 	 	 	 
	(c) After (b) but
prior to obtaining
marketing approval
from a Regulatory
Authority
	 	 	20	%	 	 	80	%
	 
	 	 	 	 	 	 	 	 
	(d) After (c)
	 	 	15	%	 	 	85	%

6.5.1 Third Party Payments on Non-Royalty Revenue. Isis will be solely responsible for
passing through the Third Party Payments owing to [***] and [***] on Non-Royalty Revenue, if any.

Section 6.6 Timing of Non-Royalty Revenue Payments. Isis share of Non-Royalty Revenue calculated
in Section 6.5 will become due and payable within twenty-one (21) days after receipt of the
applicable Non-Royalty Revenue by OncoGenex.

Section 6.7 Payment Method. Any amounts due to Isis pursuant to this Agreement will be paid in
U.S. dollars by wire transfer in immediately available funds to an account designated by Isis. Any
payments or portions thereof due hereunder which are not paid on the date such payments are due
under this Agreement will bear interest at a rate equal to the lesser of the prime rate as
published in The Wall Street Journal, Eastern Edition, on the first day of each calendar quarter in
which such payments are overdue, plus two percent (2%), or the maximum rate permitted by law,
whichever is lower, calculated on the number of days such payment is delinquent, compounded
monthly.

Section 6.8 Currency; Foreign Payments. If any currency conversion will be required in connection
with any payment hereunder, such conversion will be made by using the daily noon buying rates as
published by the Federal Reserve Bank of New York on the last business day of the calendar quarter
to which such payments relate. If at any time legal restrictions prevent the prompt remittance of
any payments in any jurisdiction, OncoGenex may notify Isis and make such payments by depositing
the amount thereof in local currency in a bank account or other
depository in such country in the name of Isis or its designee, and OncoGenex will have no further
obligations under this Agreement with respect thereto.

 

9

 

Section 6.9 Taxes. OncoGenex may deduct from any amounts it is required to pay to Isis pursuant to
this Agreement an amount equal to that withheld for or due on account of any taxes (other than
taxes imposed on or measured by net income) or similar governmental charge imposed on Isis by a
jurisdiction of OncoGenex (“Withholding Taxes”). OncoGenex will provide Isis a certificate
evidencing payment of any Withholding Taxes hereunder within 30 days of such payment. OncoGenex
will notify Isis as soon as practicable once OncoGenex has determined it will deduct the amount of
any Withholding Taxes from its payments to Isis under this Section 6.9. Each Party agrees to
cooperate with the other Party in claiming refunds or exemptions from such deductions or
withholdings under any relevant agreement or treaty which is in effect. The Parties shall discuss
applicable mechanisms for minimizing such taxes to extent possible in compliance with Applicable
Law. In addition, the Parties shall cooperate in accordance with Applicable Law to minimize
indirect taxes (such as value added tax, sales tax, consumption tax and other similar taxes) in
connection with this Agreement.

Section 6.10 Records Retention; Audit.

6.10.1 Regulatory Records. With respect to the subject matter of this Agreement, OncoGenex
will maintain, or cause to be maintained, records of its research, development, manufacturing and
commercialization activities, including all Regulatory Documentation, pursuant to its standard
operating procedures. All Regulatory Documentation will be retained for a period at least as may
be required by Applicable Law.

6.10.2 Record Retention. OncoGenex will maintain (and will ensure that its sublicensees will
maintain) complete and accurate books, records and accounts that fairly reflect Revenue and the
royalties payable to Isis under this Agreement (including the calculation of Net Sales and any
adjustments under Section 6.2) with respect to the Product in sufficient detail to confirm the
accuracy of any payments required hereunder and in accordance with GAAP, which books, records and
accounts will be retained until the later of (i) 3 years after the end of the period to which such
books, records and accounts pertain, and (ii) the expiration of the applicable tax statute of
limitations (or any extensions thereof), or for such longer period as may be required by Applicable
Law.

6.10.3 Audit. Isis will have the right to have an independent certified public accounting
firm of nationally recognized standing, reasonably acceptable to OncoGenex, have access during
normal business hours, and upon reasonable prior written notice, to such of the records of
OncoGenex as may be reasonably necessary to verify the accuracy of Revenues for any calendar
quarter or calendar year ending not more than 24 months prior to the date of such request;
provided, however, that Isis will not have the right to conduct more than one such audit in any
Calendar Year except as provided below. Isis will bear the cost of such audit unless the audit
reveals a variance of more than 5% from the reported results, in which case OncoGenex will bear the
cost of the audit. Isis will have the right to audit previous years, if such years have not been
previously audited, if the audit reveals a variance of more than 5% from the reported results.
Isis will bear the cost of such previous year audits unless such audits reveal a variance of more
than 5%. The results of such accounting firm will be final and binding upon each of Isis and
OncoGenex, absent manifest error.

 

10

 

6.10.4 Payment of Additional Amounts. If, based on the results of such audit, additional
payments are owed by OncoGenex under this Agreement, OncoGenex will make such additional payments,
with interest from the date originally due at the rate of 1% per month, within 60 days after the
date on which such accounting firm’s written report is delivered to OncoGenex.

6.10.5 Confidentiality. Isis will treat all information subject to review under this
Section 6.10 as OncoGenex’ Confidential Information in accordance with the confidentiality
provisions of Article 7 and will cause its accounting firm to enter into a reasonably acceptable
confidentiality agreement with OncoGenex obligating such firm to maintain all such financial
information in confidence pursuant to such confidentiality agreement. The accounting firm will
disclose to Isis only whether the reports are correct or not and the amount of any discrepancy. No
other information will be shared.

ARTICLE 7

CONFIDENTIALITY

Section 7.1 Disclosure and Use Restriction. Except as expressly provided herein, the Parties agree
that, for the Term and for five (5) years thereafter, each Party will keep completely confidential
and will not publish, submit for publication or otherwise disclose, and will not use for any
purpose except for the purposes contemplated by this Agreement, any Confidential Information
received from the other Party.

7.1.1 Authorized Disclosure. Each Party may disclose Confidential Information of the other
Party to the extent that such disclosure is:

(a) made in response to a valid order of a court of competent jurisdiction; provided, however,
that such Party will first have given notice to such other Party and given such other Party a
reasonable opportunity to quash such order and to obtain a protective order requiring that the
Confidential Information and documents that are the subject of such order be held in confidence by
such court or agency or, if disclosed, be used only for the purposes for which the order was
issued; and provided further that if a disclosure order is not quashed or a protective order is not
obtained, the Confidential Information disclosed in response to such court or governmental order
will be limited to that information which is legally required to be disclosed in response to such
court or governmental order;

(b) otherwise required by law; provided, however, that the disclosing Party will provide such
other Party with notice of such disclosure in advance thereof to the extent practicable;

(c) made by such Party to the Regulatory Authorities as required in connection with any
filing, application or request for Regulatory Approval; provided, however, that reasonable measures
will be taken to assure confidential treatment of such information;

 

11

 

(d) made by such Party, in connection with the performance of this Agreement, to permitted
sublicensees, licensors, directors, officers, employees, consultants, representatives or agents,
each of whom prior to disclosure must be bound by obligations of confidentiality and non-use at
least equivalent in scope to those set forth in this Article 7; or

(e) made by such Party to existing or potential acquirers; existing or potential
pharmaceutical collaborators (to the extent contemplated hereunder); investment bankers; existing
or potential investors, merger candidates, partners, venture capital firms or other financial
institutions or investors for purposes of obtaining financing; or, bona fide strategic potential
partners; each of whom prior to disclosure must be bound by obligations of confidentiality and
non-use at least equivalent in scope to those set forth in this Article 7.

Section 7.2 Publicity.

7.2.1 Press Releases Regarding Agreement. Upon execution of this Agreement, the Parties shall
issue a joint press release announcing the existence of this Agreement in a form and substance
agreed to in writing by the Parties. Each Party agrees not to issue any other press release or
other public statement disclosing other information relating to this Agreement or the transactions
contemplated hereby without the prior written consent of the other Party, except for those
communications required by Applicable Law or court order, disclosures of information for which
consent has previously been obtained, and information of a similar nature to that which has been
previously disclosed publicly with respect to this Agreement, each of which will not require
advance approval, but will be provided to the other Party as soon as practicable after the release
or communication thereof.

7.2.2 Press Releases Regarding Products.

(a) OncoGenex may publish, present or otherwise disclose results regarding OGX-011 or Product
to the public at its sole discretion; however, any press release or other similar public
communication by either Party related to a Product’s efficacy or safety data and/or results, will
be submitted to the other Party for review at least 4 Business Days in advance of such proposed
public disclosure. Notwithstanding the foregoing, if the Party is making a disclosure that is
reasonably required by applicable law, regulation or court order and cannot practically submit the
disclosure to the other Party within the 4 Business Day advance notice period above, the disclosing
Party may provide the other Party the disclosure [***] advance notice as is practical under the
circumstances, but in any event at least [***] written notice. OncoGenex may satisfy its notice
obligation under this Section 7.2.2(a) by emailing and telephoning either Isis’ Chief Executive
Officer or Chief Operating Officer, and Isis may satisfy its notice obligation under this
Section Section 7.2.2(a) by emailing and telephoning OncoGenex’ Chief Executive Officer.

(b) In addition, each Party will immediately notify (and provide as much advance notice as
possible to) the other of any event materially related to Product (including any regulatory
approval) so that the Parties may analyze the need to or desirability of publicly disclosing or
reporting such event.

 

12

 

ARTICLE 8

TECHNOLOGY AND PATENTS

Section 8.1 Ownership.

8.1.1 Ownership of Technology and Patents.

(a) As between OncoGenex and Isis, Isis will solely own all right, title and interest to the
Isis Core Technology, Isis Core Technology Patents, Isis Manufacturing Technology and Isis
Manufacturing Patents.

(b) As between OncoGenex and Isis, OncoGenex will solely own all right, title and interest to
the OncoGenex Technology and OncoGenex Technology Patents.

(c) Except as otherwise set forth in clauses (a) and (b) above, and in Section 4.2.1, as
between OncoGenex and Isis, (i) OncoGenex will solely own all right, title and interest in all
discovery, invention, data, information, trade secret, know-how or other technology (the
“Technology”) conceived or reduced to practice solely by employees or agents of OncoGenex, together
with all patents and other intellectual property rights therein and thereto; (ii) Isis will solely
own all right, title and interest in and to all Technology conceived or reduced to practice solely
by employees or agents of Isis, together with all patents and other intellectual property rights
therein and thereto; and (iii) OncoGenex and Isis will jointly own all right, title and interest in
all Joint Technology, together with all patents and other intellectual property rights therein and
thereto. Each party will have the right, subject to the provisions of this Agreement, to freely
exploit, transfer, license or encumber its rights in any Joint Patents without the consent of, or
payment or accounting to, the other party.

8.1.2 Ownership of Regulatory Documentation. All Regulatory Documentation with respect to the
Product will be owned by OncoGenex.

Section 8.2 Prosecution of Patents.

8.2.1 Isis Rights. Isis will have the sole right, at its cost and expense and at its sole
discretion, to obtain, prosecute and maintain throughout the world the Isis Patent Rights,
including, but not limited to the Isis Core Technology Patents and the Isis Manufacturing Patents,
but excluding the Product-Specific Technology Patents and the Joint Patents. Isis will keep
OncoGenex informed of the status of all Isis Core Technology Patents and Isis Manufacturing Patents
by way of an annual listing and reasonably detailed written status report.

8.2.2 OncoGenex Rights. OncoGenex will have the sole right, at its cost and expense and at its
sole discretion, to file, obtain, prosecute and maintain throughout the world any OncoGenex
Technology Patents, Product-Specific Technology Patents and the Joint Patents.

8.2.3 Cooperation. Each Party will cooperate in the preparation, filing, prosecution, and
maintenance of the other Party’s Patents, the Product-Specific Technology Patents and the Joint
Patents, as required. Such cooperation includes promptly executing all papers and instruments and
requiring employees to execute such papers and instruments as reasonable and
appropriate so as to enable such other Party, to file, prosecute, and maintain its Patents in
any country.

 

13

 

Section 8.3 Enforcement of Patents.

8.3.1 Rights and Procedures. If Isis or OncoGenex determines that any Isis Patent Rights or
OncoGenex Patent Rights are being infringed by a Third Party’s activities and that such
infringement could affect the exercise by OncoGenex of its rights under this Agreement, it will
promptly notify the other Party in writing and provide such other Party with any evidence of such
infringement that is reasonably available.

(a) Isis Core Technology Patents and Isis Manufacturing Patents. Subject to 8.3.1(e) Isis
will have the sole right, but not the obligation, at its own expense, to remove infringement of
Isis Core Technology Patents and Isis Manufacturing Patents using commercially appropriate steps,
including the filing of an infringement suit or taking other similar action, and OncoGenex or a
Third Party licensee of the Product will have the right, at its own expense, to be represented in
any such action; provided, however, that (i) if Isis fails to bring an action or proceeding within
ninety (90) days following notice of such infringement, or earlier notifies OncoGenex or a Third
Party licensee of the Product in writing of its intent not to take such steps, and (ii) the
infringement is likely to have a material adverse effect on OncoGenex’ or a sub-licensee’
development, manufacture, production, release or commercialization of the Product, then OncoGenex
and/or the Third Party licensee of the Product will meet with Isis to determine whether to defend
against such infringement, and if the Parties mutually agree in writing to proceed in defending
such infringement, Isis will remove the infringement using commercially appropriate steps, and
OncoGenex or the Third Party will share in the reasonable costs incurred relating to the removal of
any such infringement on an equal basis. If however, (i) the Parties cannot mutually agree in
writing to proceed in removing such infringement, (ii) the product in question is a Competing
Product, and (iii) OncoGenex requests in writing that Isis remove such infringement (an “OncoGenex
Mandate”), then Isis (at OncoGenex’ sole expense) will remove the infringement using commercially
appropriate steps. In either case, Isis may not settle, or otherwise consent to an adverse
judgment in, such infringement that diminishes the rights or interests of OncoGenex without the
prior express written consent of OncoGenex.

(b) In the event of an (i) OncoGenex Mandate (ii) Isis refuses to remove the infringement in a
country using commercially appropriate steps (as determined, if necessary, in accordance with the
dispute resolution provisions in Section 13.15) and (iii) such Competing Product is actually being
sold in such country, then the [***].

(c) OncoGenex Technology Patents. Subject to 8.3.1(e) OncoGenex will have the sole right, but
not the obligation, at its own expense, to remove infringement of OncoGenex Technology Patents
using commercially appropriate steps, including the filing of an infringement suit or taking other
similar action, and Isis will have the right, at its own expense, to be represented in any such
action.

 

14

 

(d) Product-Specific Technology Patents and Joint Patents. Subject to 8.3.1(e) OncoGenex will
have the sole right, but not the obligation, at its own expense, to
remove infringement of Product-Specific Technology Patents and Joint Patents using
commercially appropriate steps, including the filing of an infringement suit or taking other
similar action, and Isis will have the right, at its own expense, to be represented in any such
action; provided, however, that if the Product has not been sublicensed to a Third Party and
OncoGenex fails to bring an action or proceeding within ninety (90) days following notice of such
infringement, or earlier notifies Isis in writing of its intent not to take such steps, Isis will
have the right to do so at its expense, and OncoGenex will have the right, at its own expense, to
be represented in any such action. Notwithstanding the foregoing, if the infringement is likely to
have a material adverse effect on Isis’ economic interest in the Product’s development or
commercialization, Isis and OncoGenex will meet to determine whether to defend against such
infringement, and if the Parties mutually agree to proceed in defending such infringement,
OncoGenex will remove the infringement using commercially appropriate steps, and Isis and OncoGenex
will share in the reasonable costs incurred relating to the removal of any such infringement on an
equal basis.

(e) Cooperation. The Party not enforcing the applicable Patent will provide reasonable
assistance to the other Party, including, but not limited to, providing access to relevant
documents and other evidence, making its employees available at reasonable business hours, and
joining the action to the extent necessary to allow the enforcing Party to maintain the action.

8.3.2 Recovery. Any amounts recovered by either or both Parties, including Third Party
licensees in connection with or as a result of any action contemplated by Section 8.3.1, whether by
settlement or judgment, will be used to reimburse the Parties, including Third Party licensees for
their reasonable costs and expenses in making such recovery (which amounts will be allocated pro
rata if insufficient to cover the totality of such expenses). Furthermore, if Isis is enforcing
Party under Section 8.3.1(a) or OncoGenex is the enforcing party, after reimbursing the Parties in
accordance with the preceding sentence, OncoGenex will retain any remainder of the recovery as Net
Sales and royalties will be payable by OncoGenex to Isis with respect to such Net Sales in
accordance with this Agreement. If Isis is the enforcing party other than as set forth in
Section 8.3.1(a), after reimbursing the Parties in accordance with the first sentence of this
Section, any remainder will be kept by Isis.

Section 8.4 Third Party Litigation. In the event that a Third Party institutes a patent
infringement suit (including any suit alleging the invalidity or unenforceability of the Patents of
a Party) against either Party or Third Party licensees during the Term of this Agreement, alleging
that any of the activities hereunder infringes one or more patent or other intellectual property
rights held by such Third Party (an “Infringement Suit”), the Parties will cooperate with one
another in defending such suit. Isis will have the sole right to control any defense of any such
claim involving alleged infringement of Third Party rights by Isis’ activities at its own expense
and by counsel of its own choice, and OncoGenex will have the right, at its own expense, to be
represented in any such action by counsel of its own choice. OncoGenex will have the sole right to
control any defense of any such claim involving alleged infringement of Third Party rights by
OncoGenex’ activities, or that relates to the development, manufacture, production, release and
commercialization of the Product, at its own expense and by counsel of its own choice, and Isis
will have the right, at its own expense, to be represented in any such action by additional counsel
of its own choice at its own expense.

 

15

 

Section 8.5 No Challenge. During the term of this Agreement, OncoGenex, its Affiliates and
sublicensees will not, directly or indirectly, and will not collaborate with, or otherwise
authorize any Third Party to challenge any Isis Patent Rights licensed by Isis to OncoGenex under
this Agreement, including through opposition, re-examination, nullity or revocation proceeding, or
other available administrative mechanism; provided, however, that, notwithstanding the foregoing,
OncoGenex, its Affiliates and sublicensees shall have the right to comply with a subpoena duly
issued in good faith by a Third Party, court or administrative order, or similar legal process for
testimony or the production of documents.

ARTICLE 9

TERM AND TERMINATION

Section 9.1 Term. The term of this Agreement (the “Term”) will continue in effect until such time
as any Product is no longer being developed, manufactured, produced, released or commercialized
hereunder, or unless terminated at an earlier date in accordance with the terms and conditions set
forth in this Article 9. Isis will have the right to terminate this Agreement and/or any license
granted by it hereunder solely in accordance with Article 12.

Section 9.2 Rights in Bankruptcy. All rights and licenses granted under or pursuant to this
Agreement by Isis to OncoGenex are, and will otherwise be deemed to be, for purposes of Section
365(n) of the United States Bankruptcy Code, licenses of rights to “intellectual property” as
defined under Section 101 of the United States Bankruptcy Code. The Parties agree that OncoGenex,
as a licensee of such rights under this Agreement, will retain and may fully exercise all of its
rights and elections under the United States Bankruptcy Code. The Parties further agree that, in
the event of the commencement of a bankruptcy proceeding by or against Isis under the United States
Bankruptcy Code, OncoGenex will be entitled to a complete duplicate of (or complete access to, as
appropriate) any such intellectual property and all embodiments of such intellectual property,
which, if not already in OncoGenex’ possession, will be promptly delivered to it (a) upon any such
commencement of a bankruptcy proceeding upon OncoGenex’ written request therefor, unless Isis
elects to continue to perform all of its obligations under this Agreement or (b) if not delivered
under clause (a) above, following the rejection of this Agreement by or on behalf of Isis upon
written request therefor by OncoGenex.

Section 9.3 Consequences of Expiration or Termination.

9.3.1 Licenses. Upon expiration of the Term of this Agreement in accordance with Section
Section 9.1 and payment of all amounts owed pursuant to this Agreement, the licenses granted by
Isis to OncoGenex hereunder will terminate.

9.3.2 Return of Information and Materials. Upon expiration of this Agreement pursuant to
Section Section 9.1 or upon termination of this Agreement in its entirety by either Party pursuant
to this Article 9, each Party, at the request of the other Party, will return all data, files,
records and other materials in its possession or control relating to such other Party’s Technology,
or containing or comprising such other Party’s Information and Inventions or other Confidential
Information and, in each case, to which the returning Party does not retain rights
hereunder (except one copy of which may be retained for archival purposes). Notwithstanding
the foregoing, each Party may retain one (1) copy of the other Party’s Confidential Information for
its legal archives.

 

16

 

Section 9.4 Accrued Rights; Surviving Obligations.

9.4.1 Accrued Rights. Termination or expiration of this Agreement for any reason will be
without prejudice to any rights or financial compensation that will have accrued to the benefit of
a Party prior to such termination or expiration. Such termination or expiration will not relieve a
Party from obligations that are expressly indicated to survive the termination or expiration of
this Agreement.

9.4.2 Survival. Articles 7, 10, 12 and 13 of this Agreement, and Sections 4.2.1, 6.10, 8.1,
9.3, 9.4 and 11.4 will survive expiration or termination of this Agreement for any reason.

ARTICLE 10

INDEMNIFICATION AND INSURANCE

Section 10.1 Indemnification of Isis. OncoGenex will indemnify Isis, and their respective
directors, officers, employees and agents, and defend and hold each of them harmless, from and
against any and all losses, damages, liabilities, costs and expenses (including reasonable
attorneys’ fees and expenses) but only to the extent arising from or occurring as a result of any
and all liability suits, investigations, claims, demands or actions by a Third Party (collectively,
“Losses” and each a “Loss”) to the extent arising from or occurring as a result of (a) whether or
not negligence is found, the development, manufacture, use, handling, storage, sale or other
commercialization or disposition of OGX-011 or any Product by OncoGenex or its Affiliates or
licensees, (b) any material breach by OncoGenex of this Agreement, or (c) the gross negligence or
willful misconduct on the part of OncoGenex or its licensees or sublicensees in performing any
activity contemplated by this Agreement, except for those Losses for which Isis has an obligation
to indemnify OncoGenex pursuant to Section 10.2, as to which Losses each Party will indemnify the
other to the extent of their respective liability for the Losses.

Section 10.2 Indemnification of OncoGenex. Isis will indemnify OncoGenex, and their respective
directors, officers, employees and agents, and defend and save each of them harmless, from and
against any and all Losses to the extent arising from or occurring as a result of (a) any material
breach by Isis of this Agreement, or (b) the gross negligence or willful misconduct on the part of
Isis or its licensees or sublicensees in performing any activity contemplated by this Agreement,
except for those Losses for which OncoGenex has an obligation to indemnify Isis pursuant to Section
9.1, as to which Losses each Party will indemnify the other to the extent of their respective
liability for the Losses.

Section 10.3 Indemnification Procedure.

10.3.1 Notice of Claim. The indemnified Party will give the indemnifying Party prompt written
notice (an “Indemnification Claim Notice”) of any Loss upon which such indemnified Party intends to
base a request for indemnification under Section 10.1 or Section 10.2, but in no event will the
indemnifying Party be liable for any Losses that result from any delay in providing such notice.
Each Indemnification Claim Notice must contain a description of the Loss and the
nature and amount of such Loss (to the extent that the nature and amount of such Loss are
known at such time). The indemnified Party will furnish promptly to the indemnifying Party copies
of all papers and official documents received in respect of such Loss. All indemnification claims
in respect of a Party, its Affiliates or their respective directors, officers, employees and agents
(collectively, the “Indemnitees” and each an “Indemnitee”) will be made solely by such Party to
this Agreement (the “Indemnified Party”).

 

17

 

10.3.2 Third Party Claims. The obligations of an indemnifying Party under this Article 10
with respect to Losses arising from claims of any Third Party that are subject to indemnification
as provided for in Section 10.1 or 10.2 (a “Third Party Claim”) will be governed by and be
contingent upon the following additional terms and conditions:

(a) Control of Defense. At its option, the indemnifying Party may assume the defense of any
Third Party Claim by giving written notice to the Indemnified Party within 30 days after the
indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defense of
a Third Party Claim by the indemnifying Party will not be construed as an acknowledgment that the
indemnifying Party is liable to indemnify any Indemnitee in respect of the Third Party Claim, nor
will it constitute a waiver by the indemnifying Party of any defenses it may assert against any
Indemnitee’s claim for indemnification. Upon assuming the defense of a Third Party Claim, the
indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal
counsel selected by the indemnifying Party. In the event the indemnifying Party assumes the
defense of a Third Party Claim, the Indemnified Party will immediately deliver to the indemnifying
Party all original notices and documents (including court papers) received by any Indemnitee in
connection with the Third Party Claim. Should the indemnifying Party assume the defense of a Third
Party Claim, the indemnifying Party will not be liable to the Indemnified Party or any other
Indemnitee for any legal expenses subsequently incurred by such Indemnified Party or other
Indemnitee in connection with the analysis, defense or settlement of the Third Party Claim. In the
event that it is ultimately determined that the indemnifying Party is not obligated to indemnify,
defend or hold harmless an Indemnitee from and against the Third Party Claim, the Indemnified Party
will reimburse the indemnifying Party for any and all costs and expenses (including attorneys’ fees
and costs of suit) and any Losses incurred by the indemnifying Party in its defense of the Third
Party Claim with respect to such Indemnitee.

(b) Right to Participate in Defense. Without limiting Section 10.3.2(a), any Indemnitee will
be entitled to participate in, but not control, the defense of such Third Party Claim and to employ
counsel of its choice for such purpose; provided, however, that such employment will be at the
Indemnitee’s own expense unless (i) the employment thereof has been specifically authorized by the
indemnifying Party in writing, or (ii) the indemnifying Party has failed to assume the defense and
employ counsel in accordance with Section 10.3.2(a) (in which case the Indemnified Party will
control the defense).

 

18

 

(c) Settlement. With respect to any Losses relating solely to the payment of money damages in
connection with a Third Party Claim and that will not result in the Indemnitee’s becoming subject
to injunctive or other relief or otherwise adversely affect the business of the Indemnitee in any
manner, and as to which the indemnifying Party will have acknowledged in writing the obligation to
indemnify the Indemnitee hereunder, the indemnifying
Party will have the sole right to consent to the entry of any judgment, enter into any
settlement or otherwise dispose of such Loss, on such terms as the indemnifying Party, in its sole
discretion, will deem appropriate. With respect to all other Losses in connection with Third Party
Claims, where the indemnifying Party has assumed the defense of the Third Party Claim in accordance
with Section 9.3.2(a), the indemnifying Party will have authority to consent to the entry of any
judgment, enter into any settlement or otherwise dispose of such Loss provided it obtains the prior
written consent of the Indemnified Party (which consent will not be unreasonably withheld or
delayed). The indemnifying Party will not be liable for any settlement or other disposition of a
Loss by an Indemnitee that is reached without the written consent of the indemnifying Party.
Regardless of whether the indemnifying Party chooses to defend or prosecute any Third Party Claim,
no Indemnitee will admit any liability with respect to, or settle, compromise or discharge, any
Third Party Claim without the prior written consent of the indemnifying Party.

(d) Cooperation. Regardless of whether the indemnifying Party chooses to defend or prosecute
any Third Party Claim, the Indemnified Party will, and will cause each other Indemnitee to,
cooperate in the defense or prosecution thereof and will furnish such records, information and
testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings,
trials and appeals as may be reasonably requested in connection therewith. Such cooperation will
include access during normal business hours afforded to the indemnifying Party to, and reasonable
retention by the Indemnified Party of, records and information that are reasonably relevant to such
Third Party Claim, and making Indemnitees and other employees and agents available on a mutually
convenient basis to provide additional information and explanation of any material provided
hereunder, and the indemnifying Party will reimburse the Indemnified Party for all its reasonable
out-of-pocket expenses in connection therewith.

(e) Expenses. Except as provided above, the reasonable and verifiable costs and expenses,
including fees and disbursements of counsel, incurred by the Indemnified Party in connection with
any claim will be reimbursed on a calendar quarter basis by the indemnifying Party, without
prejudice to the indemnifying Party’s right to contest the Indemnified Party’s right to
indemnification and subject to refund in the event the indemnifying Party is ultimately held not to
be obligated to indemnify the Indemnified Party.

Section 10.4 Insurance. OncoGenex shall maintain product liability insurance with respect to the
development, manufacture and sale of Products hereunder by OncoGenex in such amount as OncoGenex
customarily maintains with respect to the development, manufacture and sale of its similar
products, but at a minimum an amount that is customarily maintained by similar companies in the
life sciences industry with respect to the development, manufacture and sale of similar products.
OncoGenex shall maintain such insurance for so long as it continues to develop, manufacture or sell
any Product, and thereafter for so long as OncoGenex customarily maintains insurance covering the
development, manufacture or sale of its similar products. Upon Isis’ request, OncoGenex will
provide Isis with a certificate of insurance evidencing such insurance.

 

19

 

ARTICLE 11

REPRESENTATIONS AND WARRANTIES

Section 11.1 Representations, Warranties and Covenants. Each Party hereby represents, warrants and
covenants to the other Party as of the Amendment Effective Date as follows:

11.1.1 Corporate Authority. Such Party (a) has the power and authority and the legal right to
enter into this Agreement and perform its obligations hereunder, and (b) has taken all necessary
action on its part required to authorize the execution and delivery of this Agreement and the
performance of its obligations hereunder. This Agreement has been duly executed and delivered on
behalf of such Party and constitutes a legal, valid and binding obligation of such Party and is
enforceable against it in accordance with its terms subject to the effects of bankruptcy,
insolvency or other laws of general application affecting the enforcement of creditor rights and
judicial principles affecting the availability of specific performance and general principles of
equity, whether enforceability is considered a proceeding at law or equity.

11.1.2 Litigation. Such Party is not aware of any pending or threatened litigation (and has
not received any communication) that alleges that such Party’s activities related to this Agreement
have violated, or that by conducting the activities as contemplated herein such Party would
violate, any of the intellectual property rights of any other party.

11.1.3 Consents, Approvals, etc. All necessary consents, approvals and authorizations of all
Regulatory Authorities and other parties required to be obtained by such Party in connection with
the execution and delivery of this Agreement and the performance of its obligations hereunder have
been obtained.

11.1.4 Conflicts. The execution and delivery of this Agreement and the performance of such
Party’s obligations hereunder (a) do not conflict with or violate any requirement of Applicable Law
or any provision of the articles of incorporation, bylaws or any similar instrument of such Party,
as applicable, in any material way, and (b) do not conflict with, violate, or breach or constitute
a default or require any consent under, any contractual obligation or court or administrative order
by which such Party is bound.

11.1.5 No Default. Such Party is not aware of any breach by it of any representation,
warranty, or covenant in the Original Collaboration Agreement.

Section 11.2 Additional Representations and Warranties of Isis.

11.2.1 Isis represents and warrants to OncoGenex that Isis is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware, and has full
corporate power and authority and the legal right to own and operate its property and assets and to
carry on its business as it is now being conducted and as it is contemplated to be conducted by
this Agreement.

 

20

 

11.2.2 Isis represents and warrants to OncoGenex that the rights granted by Isis to OncoGenex
as set forth in Article 4 include all necessary rights of Isis’ technology, whether or not patented
or patentable, which are owned or Controlled by Isis on the Amendment Effective Date and which are
necessary or reasonably required for OncoGenex to research develop, make,
have made, use, sell, offer for sale, have sold and import the Product. Further, Isis
represents and warrants to OncoGenex that Isis has not knowingly [***] whether or not patented or
patentable, to develop, make or use OGX-011 under the Original Collaboration Agreement, that Isis
could not [***] of this Agreement or that (in the case of broadly commercially available reagents,
equipment and software) is not otherwise available on commercially reasonable terms along with the
purchase or lease of such reagents, equipment and software.

11.2.3 Isis represents and warrants to OncoGenex that (i) Section 9.6 of the [***] Agreement
states that the sublicense granted by Isis to OncoGenex under the [***] Agreement will survive
termination of the [***] Agreement, and (ii) Section 4.3(b) of the [***] Agreement provides that if
the [***] Agreement is terminated for any reason, then [***] will promptly negotiate in good faith
a direct license of the sublicensed rights, on terms substantially similar to those contained in
this Agreement, with OncoGenex, unless the actions or omissions of OncoGenex were a cause for
termination of the [***] Agreement.

Section 11.3 Additional Representations and Warranties of OncoGenex. OncoGenex represents and
warrants to Isis that OncoGenex is a corporation duly organized, validly existing and in good
standing under the laws of Canada, and has full corporate power and authority and the legal right
to own and operate its property and assets and to carry on its business as it is now being
conducted and as it is contemplated to be conducted by this Agreement.

Section 11.4 DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTIONS 11.1,
11.2 AND 11.3, ONCOGENEX AND ISIS MAKE NO REPRESENTATIONS AND GRANT NO WARRANTIES, EXPRESS OR
IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND ONCOGENEX AND ISIS
EACH SPECIFICALLY DISCLAIM ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED,
INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR
ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY
RIGHTS OF THIRD PARTIES.

ARTICLE 12

BREACH

Section 12.1 Material Breach by Isis. Failure by Isis to comply with any of its material
obligations contained herein (including, without limitation, its technology transfer obligations
under Section 4.2) will entitle OncoGenex to give Isis notice specifying the nature of the material
breach, requiring Isis to make good or otherwise cure such default, and stating its intention to
trigger the provisions of this Article 12 if such default is not cured. If such default is not
cured within ninety (90) days after the receipt of such notice (or, if such default cannot be cured
within such ninety (90) day period, if Isis does not commence actions to cure such default within
such period and thereafter diligently continue such actions or if such default is not otherwise
cured within ninety (90) days after the receipt of such notice), then OncoGenex will be entitled to
appeal to the Courts to enforce specific performance upon Isis without prejudice to any of its
other rights conferred on it by this Agreement, and in addition to any other remedies available to
the Courts as remedy for the breach and to continue to develop or commercialize the Product
independently of Isis in accordance with this Agreement.

 

21

 

Section 12.2 Breach by OncoGenex.

12.2.1 Failure to Pay. If OncoGenex is in material breach of OncoGenex’ obligation to make a
payment to Isis under Article 6, then Isis may deliver written notice of such breach to OncoGenex.
OncoGenex will have thirty (30) days following such notice to cure such breach. If OncoGenex
receives written notice of such breach and fails to cure such breach within the 30 day period, Isis
may declare a breach hereunder upon thirty (30) days advance written notice to OncoGenex and such
notice will effectively terminate this Agreement upon expiration of such thirty (30) day period.

12.2.2 Discontinued Development. In the event of a Discontinuance or if OncoGenex materially
breaches its diligence obligations under Section 4.4 which material breach is not cured by
OncoGenex within ninety (90) days after receipt of written notice from Isis describing such
material breach in reasonably specific detail, then in any such case, as Isis’ sole and exclusive
remedy therefor, Isis will have the right to terminate the [***] under [***] upon thirty (30) days
prior written notice to OncoGenex and in such case OncoGenex will grant to Isis a worldwide license
or sublicense, as the case may be, to the OncoGenex Product-Specific Technology, OncoGenex Patents,
OncoGenex Technology and any Product-Specific Technology Patents assigned to OncoGenex under
Section 4.2.1 (in the case of OncoGenex Patents and OncoGenex Technology that are the subject of
one or more Third Party agreements, such license or sublicense shall be subject to all restrictions
and obligations (including financial obligations) under such Third Party agreements) existing as of
such date solely to develop, make, have made, use, sell, offer for sale, have sold and import
Nonexclusive Clusterin ASOs (and any products containing such Nonexclusive Clusterin ASOs). For
purposes of this Section 12.2.2, “Nonexclusive Clusterin ASOs” means ASOs that act predominantly
by [***] Clusterin [***] or that are [***] to Clusterin [***] provided, however that Nonexclusive
Clusterin ASOs will not include any ASO that (a) acts to modulate [***] Clusterin and (b) either
(i) has the same [***] as OGX-011 or (ii) at the time of such Discontinuance or breach OncoGenex,
its Affiliates or sublicensees had [***] (each, an “Exclusive ASO”). Within ninety (90) days
following the effectiveness of any termination by Isis, pursuant to this Section 12.2.2, of the
[***] OncoGenex shall provide Isis with a list describing the [***].

ARTICLE 13

MISCELLANEOUS

Section 13.1 Force Majeure. Except for any failure to make any payment required under Article 6,
neither Party will be held liable or responsible to the other Party or be deemed to have defaulted
under or breached this Agreement for failure or delay in fulfilling or performing any term of this
Agreement when such failure or delay is caused by or results from events beyond the reasonable
control of the non-performing Party, including fires, floods, embargoes, shortages, epidemics,
quarantines, war, acts of war (whether war be declared or not), insurrections, riots, civil
commotion, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays
in acting by any governmental authority. The non-performing Party will notify the other Party of
such force majeure within ten (10) days after such occurrence by giving written notice to
the other Party stating the nature of the event, its anticipated duration, and any action being
taken to avoid or minimize its effect. The suspension of performance will be of no greater scope
and no longer duration than is necessary and the non-performing Party will use Commercially
Reasonable Efforts to remedy its inability to perform; provided, however, that in the event the
suspension of performance continues for one-hundred and eighty (180) days after the date of the
occurrence, the Parties will meet to discuss in good faith how to proceed in order to accomplish
the development and commercialization of the Product as set forth in this Agreement.

 

22

 

Section 13.2 Assignment. Without the prior written consent of the other Party hereto, neither
Party will sell, transfer, assign, delegate, pledge or otherwise dispose of, whether voluntarily,
involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties
hereunder; provided, however, that (i) either Party hereto may assign or transfer this Agreement or
any of its rights or obligations hereunder without the consent of the other Party to any Third
Party with which it has merged or consolidated, or to which it has transferred all or substantially
all of its assets to which this Agreement relates if in any such event the Third Party assignee or
surviving entity assumes in writing all of the assigning Party’s obligations under this Agreement
or (ii) Isis may assign or transfer its rights under Article 6 (but no liabilities) to a Third
Party in connection with a royalty (or payment) factoring transaction. Any purported assignment or
transfer in violation of this Section will be void ab initio and of no force or effect.

Section 13.3 Severability. If any provision of this Agreement is held to be illegal, invalid or
unenforceable by a court of competent jurisdiction, such adjudication will not affect or impair, in
whole or in part, the validity, enforceability, or legality of any remaining portions of this
Agreement. All remaining portions will remain in full force and effect as if the original
Agreement had been executed without the invalidated, unenforceable or illegal part.

Section 13.4 Governing Law. This Agreement will be governed by and construed in accordance with
the laws of the Province of British Columbia without reference to any rules of conflicts of laws.

Section 13.5 Notices. All notices or other communications that are required or permitted hereunder will be in
writing and delivered personally with acknowledgement of receipt, sent by facsimile (and promptly
confirmed by personal delivery, registered or certified mail or overnight courier as provided
herein), sent by nationally-recognized overnight courier or sent by registered or certified mail,
postage prepaid, return receipt requested, addressed as follows: If to OncoGenex, to:

OncoGenex Technologies Inc.

#400 — 1001 West Broadway

Vancouver, BC V6H 4B1

Attention: President

Facsimile: (604) 736-3687

 

23

 

with a copy to:

Doug Seppala

DuMoulin Black LLP

10th Floor, 595 Howe Street

Vancouver, British Columbia V6C 2T5

Facsimile: (604) 687-3635

If to Isis, to:

Isis Pharmaceuticals, Inc.

1896 Rutherford Road

Carlsbad, California 92008-7208

Attention: Executive Vice President

Facsimile: (760) 268-4922

with a copy to:

Attention: General Counsel

Facsimile: (760) 603-2707

or to such other address as the Party to whom notice is to be given may have furnished to the other
Party in writing in accordance herewith. Any such communication will be deemed to have been given
(i) when delivered, if personally delivered or sent by facsimile on a Business Day, (ii) on the
Business Day after dispatch, if sent by nationally-recognized overnight courier, and (iii) on the
third business day following the date of mailing, if sent by mail. It is understood and agreed
that this Section 13.6 is not intended to govern the day-to-day business communications necessary
between the Parties in performing their duties, in due course, under the terms of this Agreement.

Section 13.6 Entire Agreement; Modifications. This Agreement sets forth and constitutes the entire
agreement and understanding between the Parties with respect to the subject matter hereof and all
prior agreements, understanding, promises and representations, whether written or oral, with
respect thereto are superseded hereby, including without limitation the Original Collaboration
Agreement. For clarity, the Parties acknowledge and agree that the Original Collaboration
Agreement remains in effect in accordance with its terms with respect to the period between the
Start Date and the Amendment Effective Date. Each Party confirms that it is not relying on any
representations or warranties of the other Party except as specifically set forth herein. No
amendment, modification, release or discharge will be binding upon the Parties unless in writing
and duly executed by authorized representatives of both Parties.

Section 13.7 Relationship of the Parties. It is expressly agreed that the Parties will be
independent contractors of one another and that the relationship between the Parties will not
constitute a partnership, joint venture or agency. Neither Party will have the authority to make
any statements, representations or commitments of any kind, or to take any action, which will be
binding on the other, without the prior written consent of the other to do so. All persons
employed by a Party will be employees of such Party and not of the other Party and all costs and
obligations incurred by reason of any such employment will be for the account and expense of such
Party.

 

24

 

Section 13.8 Cooperation. Isis will provide reasonable assistance to OncoGenex in respect of
partnering discussions, financing activities and regulatory filings to support the development and
commercialization of the Product. Notwithstanding the foregoing, Isis will not be required to
modify or waive any provision of this Agreement in connection with partnering discussions or
financing activities to support the development and commercialization of the Product.

Section 13.9 Waiver. Any term or condition of this Agreement may be waived at any time by the
Party that is entitled to the benefit thereof, but no such waiver will be effective unless set
forth in a written instrument duly executed by or on behalf of the Party waiving such term or
condition. The waiver by either Party hereto of any right hereunder or of the failure to perform
or of a breach by the other Party will not be deemed a waiver of any other right hereunder or of
any other breach or failure by said other Party whether of a similar nature or otherwise.

Section 13.10 Counterparts. This Agreement may be executed in two (2) or more counterparts, each
of which will be deemed an original, but all of which together will constitute one and the same
instrument.

Section 13.11 No Benefit to Third Parties. The representations, warranties, covenants and
agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their
successors and permitted assigns, and they will not be construed as conferring any rights on any
other parties.

Section 13.12 Further Assurance. Each Party will duly execute and deliver, or cause to be duly
executed and delivered, such further instruments and do and cause to be done such further acts and
things, including the filing of such assignments, agreements, documents and instruments, as may be
necessary or as the other Party may reasonably request in connection with this Agreement or to
carry out more effectively the provisions and purposes, or to better assure and confirm unto such
other Party its rights and remedies under this Agreement.

Section 13.13 References. Unless otherwise specified, (a) references in this Agreement to any
Article, Section, Schedule or Exhibit will mean references to such Article, Section, Schedule or
Exhibit of this Agreement, (b) references in any section to any clause are references to such
clause of such section, and (c) references to any agreement, instrument or other document in this
Agreement refer to such agreement, instrument or other document as originally executed or, if
subsequently varied, replaced or supplemented from time to time, as so varied, replaced or
supplemented and in effect at the relevant time of reference thereto.

Section 13.14 Construction. Except where the context otherwise requires, wherever used, the
singular will include the plural, the plural the singular, the use of any gender will be applicable
to all genders and the word “or” is used in the inclusive sense (and/or). The captions of this
Agreement are for convenience of reference only and in no way define, describe, extend or limit the
scope or intent of this Agreement or the intent of any provision contained in this Agreement. The
term “including” as used herein will mean including, without limiting the generality of any
description preceding such term. The language of this Agreement will be deemed to be the
language mutually chosen by the Parties and no rule of strict construction will be applied against
either Party hereto. Appendices to this Agreement, or added hereto according to the terms of this
Agreement, are made part of this Agreement.

 

25

 

Section 13.15 Dispute Resolution Regarding Diligence.

13.15.1 General. The Parties will negotiate in good faith and use reasonable efforts to
settle any dispute, controversy or claim arising regarding whether (i) OncoGenex has satisfied its
diligence obligations under Section 4.4 of this Agreement or (ii) in the event of an OncoGenex
Mandate, Isis has refused to remove the applicable infringement using commercially appropriate
steps, by first referring such dispute to the Chief Executive Officers of each of the Parties (or
their respective designees) who will use their good faith efforts to mutually agree upon the
resolution of the dispute. If any dispute is not resolved by the Chief Executive Officers of the
Parties (or their designees) within 30 days after such dispute is referred to them, and a Party
wishes to pursue the matter, each such dispute, controversy or claim will be finally resolved by
binding arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration
Association (“AAA”), and judgment on the arbitration award may be entered in any court having
jurisdiction thereof. The arbitration will be conducted by a panel of three persons experienced in
the pharmaceutical business: within 30 days after initiation of arbitration, each party will select
one person to act as arbitrator and the two party-selected arbitrators will select a third
arbitrator within 30 days of their appointment. If the arbitrators selected by the parties are
unable or fail to agree upon the third arbitrator, the third arbitrator will be appointed by the
AAA. No individual shall be appointed to arbitrate a dispute pursuant to this Agreement unless he
or she agrees in writing to be bound by the provisions of this Section 13.15. The place of
arbitration will be Seattle, Washington. Either Party may apply to the arbitrators for interim
injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved.

13.15.2 Expenses. Except as expressly provided herein, each Party will bear its own costs and
expenses and attorneys’ fees and an equal share of the arbitrators’ and any administrative fees of
arbitration. The arbitrators shall have the authority to grant specific performance and to
allocate between the Parties the costs of arbitration in such equitable manner as they determine.
Notwithstanding the foregoing, if a Party has been found to be in material breach of this
Agreement, the defaulting Party will be responsible for both Parties’ costs and expenses (including
the costs of the arbitrators and any administrative fees of arbitration) and the reasonable
attorneys’ fees of the non-defaulting Party.

 

26

 

13.15.3 Procedure. Except to the extent necessary to confirm an award or as may be required
by law, neither a Party nor an arbitrator may disclose the existence, content, or results of an
arbitration without the prior written consent of both Parties. In no event will an arbitration be
initiated after the date when commencement of a legal or equitable proceeding based on the dispute,
controversy or claim would be barred by the applicable Province of British Columbia statute of
limitations.

13.15.4 Speedy Resolution. The Parties intend, and shall take all reasonable action as is
necessary or desirable to ensure, that there be a speedy resolution to any dispute
which becomes the subject of arbitration, and the arbitrators shall conduct the arbitration so
as to resolve the dispute as expeditiously as possible.

13.15.5 Awards. All awards shall be in writing and shall state reasons. Executed copies of
all awards shall be delivered by the arbitrators to the Parties as soon as is reasonably possible.
All awards of the arbitrators shall be final and binding on the Parties, and there shall be no
appeal of any such award whatsoever. The Parties undertake to satisfy any award without delay.

13.15.6 Except as otherwise specified in the first sentence of Section 13.15.1, no other
disputes, controversies or claims shall be subject to this Section 13.15.

The remainder of this page intentionally left blank.

 

27

 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly
authorized representatives as of the date first above written.

	 	 	 	 	 	 	 	 	 	 	 
	OncoGenex Technologies Inc.	 	 	 	ISIS Pharmaceuticals, Inc.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Per:

	 	/s/ Scott Cormack
 

Scott D. Cormack,
	 	 	 	Per:
	 	/s/ B. Lynne Parshall
 

B. Lynne Parshall
	 	 
	 

	 	President & CEO
	 	 	 	 	 	COO and CFO	 	 

 

28

 

APPENDIX A

Definitions

“Affiliate” of a party means any other party that, directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control with such first party. For
purposes of this definition only, “control” and, with correlative meanings, the terms “controlled
by” and “under common control with” will mean (a) the possession, directly or indirectly, of the
power to direct the management or policies of a party, whether through the ownership of voting
securities or by contract relating to voting rights or corporate governance, and (b) the ownership,
directly or indirectly, of more than fifty percent (50%) of the voting securities or other
ownership interest of a party; provided that, if local law restricts foreign ownership, control
will be established by direct or indirect ownership of the maximum ownership percentage that may,
under such local law, be owned by foreign interests. In addition, Regulus Therapeutics, LLC will
not be considered an Affiliate of Isis.

“Applicable Law” means the applicable laws, rules, and regulations, including any rules,
regulations, guidelines, or other requirements of the Regulatory Authorities, that may be in effect
from time to time.

“ASO” means an antisense oligonucleotide compound (reverse of the sense strand messenger RNA),
or analog, mimic or mimetic thereof, having a sequence that is at least 6 bases long and that
modulates expression of a gene target via the binding, partially or wholly, of such compound to a
mRNA or pre-mRNA of such gene target.

“Business Day” means any day, other than Saturday, Sunday or any statutory holiday in the
Province of British Columbia or the United States.

“Calendar Year” means each successive period of 12 months commencing on January 1 and ending
on December 31.

“Clusterin” means the gene target, official symbol CLU, which is also referred to as
Testosterone Repressed Prostatic Message -2 (TRPM-2), and Sulphated Glycoprotein-2 (SGP-2).

“Commercialization Agreement” has the meaning set forth in 6.2.2.

“Commercially Reasonable Efforts” means, with respect to the research, development,
manufacture, release or commercialization of the Product, efforts and resources commonly used in
the biotechnology industry for products of similar commercial potential at a similar stage in its
lifecycle, taking into consideration their safety and efficacy, cost to develop, priority in
relation to other products under development by the other Party, the competitiveness of alternative
products, proprietary position, the likelihood of regulatory approval, profitability, and all other
relevant factors.

 

A-1

 

“Competing Product” means a product containing an ASO that (i) acts predominantly by [***]
Clusterin [***] or that is [***] Clusterin [***] (ii) [***] covered by a Valid Claim within the
Product-Specific Technology Patents in the relevant country, but for the expiration, invalidity,
revocation or unenforceability of such Product-Specific Technology Patents (such invalidity,
revocation or unenforceability as determined by a decision of a court or other governmental agency
of competent jurisdiction, unappealable or unappealed), and (iii) [***] by a Valid Claim within the
Isis Core Technology Patents in the relevant country.

“Confidential Information” means all information and know-how and any tangible embodiments
thereof provided by or on behalf of one Party to the other Party either in connection with the
discussions and negotiations pertaining to this Agreement or in the course of performing this
Agreement, including data; knowledge; practices; processes; ideas; research plans; engineering
designs and drawings; research data; manufacturing processes and techniques; scientific,
manufacturing, marketing and business plans; and financial and personnel matters relating to the
disclosing Party or to its present or future products, sales, suppliers, customers, employees,
investors or business. For purposes of this Agreement, notwithstanding the Party that disclosed
such information or know-how, all information or know-how of OncoGenex will be Confidential
Information of OncoGenex, and all information and know-how of Isis will be Confidential Information
of Isis.

Notwithstanding the foregoing, information or know-how of a Party will not be deemed
Confidential Information for purposes of this Agreement if such information or know-how:

(a) was already known to the receiving Party, other than under an obligation of
confidentiality or non-use, at the time of disclosure to such receiving Party;

(b) was generally available or known to parties reasonably skilled in the field to which such
information or know-how pertains, or was otherwise part of the public domain, at the time of its
disclosure to, or, with respect to know-how, discovery or development by, such receiving Party;

(c) became generally available or known to parties reasonably skilled in the field to which
such information or know-how pertains, or otherwise became part of the public domain, after its
disclosure to such receiving Party through no fault of the receiving Party;

(d) was disclosed to such receiving Party, other than under an obligation of confidentiality
or non-use, by a Third Party who had no obligation to the Party that Controls such information and
know-how not to disclose such information or know-how to others; or

(e) was independently discovered or developed prior to disclosure by such receiving Party, as
evidenced by their written records, without the use of Confidential Information belonging to the
Party that Controls such information and know-how.

 

A-2

 

Specific aspects or details of Confidential Information will not be deemed to be within the
public domain or in the possession of a Party merely because the Confidential Information is
embraced by more general information in the public domain or in the possession of such Party.
Further, any combination of Confidential Information will not be considered to be in the public
domain or in the possession of a Party merely because individual elements of such Confidential
Information are in the public domain or in the possession of such Party unless the combination and
its principles are in the public domain or in the possession of such Party.

“Control” means, with respect to any Patent or other intellectual property right, possession
of the right (whether by ownership, license or otherwise), to assign, transfer, or grant a license,
sublicense or other right to or under, such Patent or right as provided for herein without
violating the terms of any agreement or other arrangement with any Third Party.

“Discontinuance” means OncoGenex voluntarily elects to abandon [***] developing OGX-011 and/or
Products, as evidenced by a written communication from an authorized officer of OncoGenex to Isis.

“FDA” means the United States Food and Drug Administration and any successor agency thereto.

“FTE” means the equivalent of the work of one employee full time for one year (consisting of
at least a total of 45.5 weeks or 1,820 hours per year (excluding vacations and holidays) of work
on or directly related to the Agreement), carried out by an Isis employee. The FTE rate will be
(i) [***] (U.S.) per FTE for any of the following activities: drug substance manufacturing;
analytical chemistry; process chemistry; formulation; raw material ordering and handling; quality
control; or manufacturing technology transfer; and (ii) [***] (U.S.) per FTE for any of the
following activities: toxicology; pharmacokinetics/metabolism; regulatory; clinical development;
or data management. These FTE rates will be adjusted upward on a Calendar Year basis commencing
January 1, 2009 (and on January 1 of each year thereafter during the Term of this Agreement) by a
factor which reflects [***] for [***] during the Term of the Agreement when compared to the [***]
in the preceding year.

“GAAP” means generally accepted accounting principles of the United States consistently
applied.

“Generic Product(s)” means a product or products containing an active ingredient having the
same or substantially the same chemical structure as the applicable ASO targeting Clusterin that is
the active ingredient contained in the applicable Product, whether approved under an NDA, ANDA, an
application under 505(b)(2), or any equivalent thereof, or otherwise by a Regulatory Authority
within the applicable country.

[***] means [***], a biotech company with head office in [***].

[***]

[***] means those patents listed in Appendix B.

 

A-3 

 

“Improvements” means any enhancement or improvement (in each case, whether or not patented or
patentable) to the Isis Core Technology or the Isis Manufacturing Technology.

“Isis Core Technology” means any discovery, invention, composition, method, process,
procedure, data, information, know-how or other technology (in each case, whether or not patented
or patentable) that is Controlled by Isis as of the Amendment Effective Date and that either
(i) was not conceived, discovered, developed or otherwise made under or in connection with the
Original Collaboration Agreement, and the application of which has utility only with respect to
Products, or (ii) is necessary or useful for the development or commercialization of Products, and
the application of which has utility both with respect to Products and other compositions. Isis
Core Technology excludes the Isis Manufacturing Technology and Product-Specific Technology.

“Isis Core Technology Patents” means Patents Controlled by Isis that claim the Isis Core
Technology on the Amendment Effective Date; provided however that Isis Core Technology Patents
excludes the Isis Manufacturing Patents and Product-Specific Technology Patents. The Isis Core
Technology Patents include, but are not limited to, the patents listed on Appendix D attached
hereto.

“Isis Manufacturing Patents” means Patents Controlled by Isis that claim the manufacturing
production and release processes (a) that were used to manufacture MOE Gapmers on the Amendment
Effective Date and embodied in the [***], or (b) that are Controlled by Isis on or after the
Amended Effective Date and otherwise are necessary, or are required by a Regulatory Authority, to
be used in the manufacture of a Product. The Isis Manufacturing Patents are listed on Appendix E
attached hereto. Manufacturing for this purpose includes synthesis, purification and analysis.

“Isis Manufacturing Technology” means (a) the Isis Manufacturing Patents, (b) the Release
Method, and (c) all other trade secret, know-how or other information or technology (i) that is
Controlled by Isis as of the Amendment Effective Date and is applicable to the manufacture,
production or release processes for the Product and embodied in the [***] or (ii) that is
Controlled by Isis after the Amendment Effective Date and otherwise is necessary, or is required by
a Regulatory Authority, to be used in the manufacture of a Product.

“Isis Patent Rights” means Isis Core Technology Patents and Isis Manufacturing Patents.

“Joint Patents” means all Patents that claim, cover or disclose the Joint Technology.

“Joint Technology” means any discovery, invention, composition, method, process, procedure,
data, information, trade secret, know-how or other technology (in each case, whether or not
patented or patentable) which is conceived, discovered, developed or otherwise made jointly by Isis
and OncoGenex (as determined in
accordance with U.S. patent law). Joint Technology excludes the Product-Specific Technology.

 

A-4 

 

“MOE Gapmer” means “2’MOE Gapmers” or an antisense phosphorothioate oligonucleotide of 15-30
nucleotides wherein all of the backbone linkages are modified by adding a sulfur at the
non-bridging oxygen (phosphorothioate) and a stretch of at least 10 consecutive nucleotides remain
unmodified (deoxy sugars) and the remaining nucleotides contain an
O’-methyl O’-ethyl substitution
at the 2’ position (MOE).

“Net Sales” means the gross invoice price of the Product sold by OncoGenex and sublicensees to
a Third Party which is not a sublicensee of the selling party (unless such sublicensee is the end
user of the Product, in which case the amount billed therefor will be deemed to be the amount that
would be billed to a Third Party in an arm’s-length transaction) for sales of such Product to such
end users less the following items, as allocable to such Product (if not previously deducted from
the amount invoiced): (i) cash, quantity and trade discounts, credits, allowances or other price
reductions for such Product given to such end user, (ii) credits, discounts, rebates, chargebacks
or allowances additionally granted (A) upon returns, rejections or recalls (except where any such
recall arises out of the Party or its sublicensee’s gross negligence, willful misconduct or fraud)
or (B) for nonconforming, damaged, out-dated and returned Product, (iii) freight, shipping and
insurance charges, (iv) taxes, duties, tariffs, surcharges or other governmental charges (other
than income taxes), (v) government mandated rebates, and (vi) a reasonable allowance for
uncollectible or bad debts determined in accordance with generally accepted accounting principles
consistently applied.

“Nonexclusive Clusterin ASO” has the meaning set forth in Section 12.2.2.

“Non-Royalty Revenue” means all Revenue received by OncoGenex with the exception of Royalty
Revenue and OncoGenex Direct Sales.

[***]

[***]

[***]

“OGX-011” means an antisense inhibitor of Clusterin having the sequence [***] where underlined
residues are
2’-methoxyethylnucleosides (MOE) and phosphorothioate linkages throughout, also
referred to as OGX-011 or ISIS 112989.

“OncoGenex Direct Sales” means Net Sales made by OncoGenex to a Third Party which is not a
sublicensee of OncoGenex.

“OncoGenex Patent Rights” means any Patents Controlled by OncoGenex.

 

A-5 

 

“OncoGenex Technology” means any discovery, invention, composition, method, process,
procedure, data, information, trade secret, know-how or other technology (in each case, whether or
not patented or patentable) that is Controlled by
OncoGenex and that is or relates to an ASO targeting Clusterin or a method of using an
antisense inhibitor of Clusterin, or otherwise is necessary or useful for the development,
manufacture, production or commercialization of Products. OncoGenex Technology excludes
Product-Specific Technology.

“OncoGenex Technology Patents” means all Patents that claim, cover or disclose the OncoGenex
Technology.

“Patents” will include (i) all U.S. patents and patent applications, (ii) any substitutions,
divisions, continuations, continuations-in-part, reissues, renewals, registrations, confirmations,
re-examinations, extensions, supplementary protection certificates and the like, and any
provisional applications, of any such patents or patent applications, and (iii) any foreign or
international equivalent of any of the foregoing.

“Permitted License” means a license under the Isis Core Technology Patents or the Isis
Manufacturing Patents (but not under the Product-Specific Technology Patents) (i) granted by Isis
to a Third Party to use ASOs solely to conduct such Third Party’s own internal Research, or
(ii) granted by Isis to a Third Party (provided that such Third Party is [***] and neither such
Third Party nor any of its Affiliates is [***] to manufacture ASOs solely for unaffiliated third
parties; provided, however, in each case, any such ASOs are not specified in such license or a
related document to be ASOs (a) that act predominantly by [***] Clusterin [***] or (b) that are
[***] Clusterin [***] or products containing such ASOs. For purposes of clarification, a Permitted
License shall not permit Isis or its Affiliates to supply to a Third Party ASOs that act
predominantly by [***] Clusterin [***] or that are [***] Clusterin [***] or products containing
such ASOs.

“Product” means any pharmaceutical preparation (in intravenous, subcutaneous, oral or any
other formulation) containing as the sole active pharmaceutical ingredient either (a) OGX-011, or
(b) any other ASO targeting Clusterin that either (i) was identified under the Original
Collaboration Agreement or (ii) is identified under Section 4.1.3.
For clarity, the Product may be used in association with other products such as chemotherapy,
hormone ablation therapy and radiation therapy and the immediately preceding sentence does not
limit such intended use.

“Product-Specific Technology” means any discovery, invention, composition, method, process,
procedure, data, information, trade secret, know-how or other technology (in each case, whether or
not patented or patentable) which is conceived, discovered, developed or otherwise made solely by
Isis or OncoGenex, or jointly by Isis and OncoGenex, under or in connection with the Original
Collaboration Agreement or this Agreement, and the application of which has utility only with
respect to Products. For purposes of clarification Product-Specific Technology excludes the Isis
Manufacturing Technology and Isis Core Technology.

“Product-Specific Technology Patents” means all Patents that claim, cover or disclose
Product-Specific Technology. Product-Specific Technology Patents include, but are not limited to
the patents listed on Appendix G attached hereto. For purposes of clarification, any
Product-Specific Technology Patents assigned to OncoGenex as set
forth in Section 4.2.1 or 8.2.2 will still be considered Product-Specific Technology Patents for determining the royalty term and
applicable royalty rates under Article 6.

 

A-6 

 

“Qualified Partner” means a corporation or other entity (a) whose primary business is the
commercialization of pharmaceutical products, (b) which, on its own or in connection with a Third
Party, does not operate a contract oligonucleotide manufacturing business and (c) is approved as
Qualified Partner by Isis at the request of OncoGenex (or its Affiliate), such approval not to be
unreasonably withheld.

“Registration Clinical Trial” means a clinical study (whether or not denominated as a “Phase
III” clinical study under applicable regulations) in human patients that is of size and design
appropriate to establish that the Product is safe and effective for its intended use, to define
warnings, precautions and adverse reactions that are associated with the Product in the dosage
range to be prescribed, and to support approval from the applicable Regulatory Authority sufficient
for the manufacture, distribution, use and sale of the Product in such jurisdiction in accordance
with Applicable Laws.

“Regulatory Authority” means any applicable government entities regulating or otherwise
exercising authority with respect to the development and commercialization of the Product.

“Regulatory Documentation” means all applications, registrations, licenses, authorizations
and approvals (including all regulatory approvals), all correspondence submitted to or received
from Regulatory Authorities (including minutes and official contact reports relating to any
communications with any Regulatory Authority), all supporting documents and all clinical studies
and tests, including the manufacturing batch records, relating to the Product, and all data
contained in any of the foregoing, including all regulatory drug lists, advertising and promotion
documents, adverse event files and complaint files.

“Release Method” means the methods used by Isis as at the Amendment Effective Date for the
release of OGX-011 utilizing liquid chromatography – mass spectrometry and specified in
Specification outlined in [***].

“Research” means in vitro or in vivo research, excluding any and all uses in humans.

“Revenue” means all revenues, receipts, monies, and the fair market value of all other
consideration directly or indirectly collected or received whether by way of cash or credit or any
barter, benefit, advantage, or concession received OncoGenex relating to the sale, license or any
other commercial transaction involving the Product, with the exception of the following: (i) any
consideration received for the reimbursement for research and development activities and (ii) any
consideration received for the fair market portion of any sale of equity or quasi-equity securities
including, without limitation, common shares and preferred shares.

 

A-7 

 

“Royalty Due Date” means March 31, June 30, September 30 and December 31 of each year during
the term of this Agreement.

“Royalty Revenue” means, with respect to a Product in a country, all Revenue received by
OncoGenex that is based on a percentage of Net Sales of such Product by a Third Party sublicensed
to sell such Product in such country.

“Start Date” means November 16, 2001.

“Supply Chain Network” will include the names, contact information, and supply description of
all providers, whether currently used or alternative preferred suppliers as of the Amendment
Effective Date, and who supply modified and unmodified nucleotides, solid support and other
reagents and raw materials specified in the Isis Manufacturing Technology.

“Third Party” means any party other than Isis or OncoGenex.

“Third Party Payments” means royalties, milestones, and other payments owing to Third Parties,
including payments as set forth in Section 6.3 and Section 6.5.

“Valid Claim” means either (a) a claim of an issued and unexpired patent included within the
Isis Patent Rights, which has not been held permanently revoked, unenforceable or invalid by a
decision of a court or other governmental agency of competent jurisdiction, unappealable or
unappealed within the time allowed for appeal, and which has not been admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise or (b) a claim of a pending patent
application included within the Isis Patent Rights, which was filed in good faith and has not been
abandoned, finally rejected or expired without the possibility of appeal or refiling, provided
however, that Valid Claim will exclude any such pending claim in an application that has not been
granted within (x) [***] years following the earliest filing date for such application in the
United States (unless and until such claim is granted), and (y) [***] years following the earliest
filing date for such application outside of the United States (unless and until such claim is
granted).

 

A-8 

 

APPENDIX B

[***]

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Patent/	 	 	 	 
	 	 	Docket #	 	Country/Treaty	 	Application #	 	Title	 	Issue Date
	[***]
	 	 	 	 	 	 	 	 	 	 
	 
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

B-1 

 

APPENDIX C

[***]

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Patent/	 	 	 	 
	Assignee	 	Docket #	 	Country/Treaty	 	Application #	 	Title	 	Issue Date
	[***]
	 	 	 	 	 	 	 	 	 	 
	 
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

C-1 

 

APPENDIX D

Isis Core Technology Patents

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Patent/	 	 	 	 
	Assignee	 	Docket #	 	Country/Treaty	 	Application #	 	Title	 	Issue Date
	ISIS
	 	 	 	 	 	 	 	 	 	 
	 
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

D-1 

 

APPENDIX E

Isis Manufacturing Patents

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Patent/	 	 	 	 
	Technology	 	Docket #	 	Country/Treaty	 	Application #	 	Title	 	Filing Date
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

E-1 

 

APPENDIX F

[***]

 

F-1 

 

APPENDIX G

Product-Specific Technology Patents

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Patent/	 	 	 	 	 	 
	Docket No.	 	Country	 	Applicaion #	 	Filing Date	 	Issue Date	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

G-1Exhibit 10.1(a)

Exhibit 10.1(a)

CREDIT LINE AGREEMENT

Borrower Agreement

BY SIGNING BELOW, THE BORROWER UNDERSTANDS, ACKNOWLEDGES AND AGREES THAT:

	A.	 	The Borrower has received and read a copy of this Borrower Agreement,
the attached Credit Line Account Application and Agreement (including
the Credit Line Agreement following this Borrower Agreement) and the
Loan Disclosure Statement explaining the risk factors that the
Borrower should consider before obtaining a loan secured by the
Borrower’s securities account. The Borrower agrees to be bound by the
terms and conditions contained in the Credit Line Account Application
and Agreement (including the Credit Line Agreement following this
Borrower Agreement) (which terms and conditions are incorporated by
reference). Capitalized terms used in this Borrower Agreement have the
meanings set forth in the Credit Line Agreement.
	 
	B.	 	THE BORROWER UNDERSTANDS AND AGREES THAT UBS BANK USA MAY DEMAND FULL
OR PARTIAL PAYMENT OF THE CREDIT LINE OBLIGATIONS, AT ITS SOLE OPTION
AND WITHOUT CAUSE, AT ANY TIME, AND THAT NEITHER FIXED RATE ADVANCES
NOR VARIABLE RATE ADVANCES ARE EXTENDED FOR ANY SPECIFIC TERM OR
DURATION. THE BORROWER UNDERSTANDS AND AGREES THAT ALL ADVANCES ARE
SUBJECT TO COLLATERAL MAINTENANCE REQUIREMENTS. THE BORROWER
UNDERSTANDS THAT UBS BANK USA MAY, AT ANY TIME, IN ITS DISCRETION,
TERMINATE AND CANCEL THE CREDIT LINE REGARDLESS OF WHETHER OR NOT AN
EVENT HAS OCCURRED.
	 
	C.	 	UNLESS DISCLOSED IN WRITING TO UBS BANK USA AT THE TIME OF THIS
AGREEMENT, AND APPROVED BY UBS BANK USA, THE BORROWER AGREES NOT TO
USE THE PROCEEDS OF ANY ADVANCE EITHER TO PURCHASE, CARRY OR TRADE IN
SECURITIES OR TO REPAY ANY DEBT (I) USED TO PURCHASE, CARRY OR TRADE
IN SECURITIES OR (II) TO ANY AFFILIATE OF UBS BANK USA. THE BORROWER
WILL BE DEEMED TO REPEAT THIS AGREEMENT EACH TIME THE BORROWER
REQUESTS AN ADVANCE.
	 
	D.	 	THE BORROWER UNDERSTANDS THAT BORROWING USING SECURITIES AS COLLATERAL
ENTAILS RISKS. SHOULD THE VALUE OF THE SECURITIES IN THE COLLATERAL
ACCOUNT DECLINE BELOW THE REQUIRED COLLATERAL MAINTENANCE
REQUIREMENTS, UBS BANK USA MAY REQUIRE THAT THE BORROWER POST
ADDITIONAL COLLATERAL, REPAY PART OR ALL OF THE BORROWER’S LOAN
AND/OR SELL THE BORROWER’S SECURITIES. ANY REQUIRED LIQUIDATIONS MAY INTERRUPT
THE BORROWER’S LONG-TERM INVESTMENT STRATEGIES AND MAY RESULT IN ADVERSE TAX
CONSEQUENCES.

 

 

 

	E.	 	Neither UBS Bank USA nor UBS Financial Services Inc.
provides legal or tax advice and nothing herein shall
be construed as providing legal or tax advice.
	 
	F.	 	Upon execution of this Credit Line Account
Application and Agreement, the Borrower declares that
all of the information requested in the Application
and supplied by the Borrower is true and accurate and
further agrees to promptly notify UBS Bank USA in
writing of any material changes to any or all of the
information contained in the Application including
information relating to the Borrower’s financial
situation.
	 
	G.	 	Subject to any applicable financial privacy laws and
regulations, data regarding the Borrower and the
Borrower’s securities accounts may be shared with UBS
Bank USA affiliates. Subject to any applicable
financial privacy laws and regulations, the Borrower
requests that UBS Bank USA share such personal
financial data with non-affiliates of UBS Bank USA as
is necessary or advisable to effect, administer or
enforce, or to service, process or maintain, all
transactions and accounts contemplated by this
Agreement.
	 
	H.	 	The Borrower authorizes UBS Bank USA and UBS
Financial Services Inc. to obtain a credit report or
other credit references concerning the Borrower
(including making verbal or written inquiries
concerning credit history) or to otherwise verify or
update credit information given to UBS Bank USA at
any time. The Borrower authorizes the release of this
credit report or other credit information to UBS Bank
USA affiliates as it deems necessary or advisable to
effect, administer or enforce, or to service, process
or maintain all transactions and accounts
contemplated by this Agreement, and for the purpose
of offering additional products, from time to time,
to the Borrower. The Borrower authorizes UBS Bank USA
to exchange Borrower information with any party it
reasonably believes is conducting legitimate credit
inquiry in accordance with the Fair Credit Reporting
Act. UBS Bank USA may also share credit or other
transactional experience with the Borrower’s
designated UBS Financial Services Inc. Financial
Advisor or other parties designated by the Borrower.
	 
	I.	 	UBS Bank USA is subject to examination by various
federal, state and self-regulatory organizations and
the books and records maintained by UBS Bank USA are
subject to inspection and subpoena by these
regulators and by federal, state, and local law
enforcement officials. The Borrower also acknowledges
that such regulators and officials may, pursuant to
treaty or other arrangements, in turn disclose such
information to the officials or regulators of other
countries, and that U.S. courts may be required to
compel UBS Bank USA to disclose such information to
the officials or regulators of other countries. The
Borrower agrees that UBS Bank USA may disclose to
such regulators and officials information about the
Borrower and transactions in the credit line account
or other accounts at UBS Bank USA without notice to
the Borrower. In addition, UBS Bank USA may in the
context of a private dispute be required by subpoena
or other judicial process to disclose information or
produce documentation related to the Borrower, the
credit line account or other accounts at UBS Bank
USA. The Borrower acknowledges
and agrees that UBS Bank USA reserves the right, in its sole discretion, to
respond to subpoenas and judicial process as it deems appropriate.

 

2

 

	J.	 	To help the government fight the funding of terrorism
and money laundering activities, Federal law requires
all financial institutions to obtain, verify, and
record information that identifies each person who
opens an account. When the Borrower opens an account
with UBS Bank USA, UBS Bank USA will ask for the
Borrower’s name, address, and other information that
will allow UBS Bank USA to identify the Borrower. UBS
Bank USA may also ask to see other identifying
documents. UBS Financial Services Inc. and UBS Bank
USA are firmly committed to compliance with all
applicable laws, rules and regulations, including
those related to combating money laundering. The
Borrower understands and agrees that the Borrower
must take all necessary steps to comply with the
anti-money laundering laws, rules and regulations of
the Borrower’s country of origin, country of
residence and the situs of the Borrower’s
transaction.
	 
	K.	 	UBS Bank USA and its affiliates will act as creditors
and, accordingly, their interests may be inconsistent
with, and potentially adverse to, the Borrower’s
interests. As a lender and consistent with normal
lending practice, UBS Bank USA may take any steps
necessary to perfect its interest in the Credit Line,
issue a call for additional collateral or force the
sale of the Borrower’s securities if the Borrower’s
actions or inactions call the Borrower’s
creditworthiness into question. Neither UBS Bank USA
nor UBS Financial Services Inc. will act as Client’s
investment advisor with respect to any liquidation.
In fact UBS Bank USA will act as a creditor and UBS
Financial Services Inc. will act as a securities
intermediary.
	 
	L.	 	The Borrower understands that, if the Collateral
Account is a managed account with UBS Financial
Services Inc., (i) in addition to any fees payable to
UBS Financial Services Inc. in connection with the
Borrower’s managed account, interest will be payable
to the Bank on an amount advanced to the Borrower in
connection with the Credit Line Account, and (ii) the
performance of the managed account might not exceed
the managed account fees and the interest expense
payable to the Bank in which case the Borrower’s
overall rate of return will be less than the costs
associated with the managed account.
	 
	M.	 	UBS Bank USA may provide copies of all credit line
account statements to UBS Financial Services Inc. and
to any Guarantor. The Borrower acknowledges and
agrees that UBS Bank USA may share any and all
information regarding the Borrower and the Borrower’s
accounts at UBS Bank USA with UBS Financial Services
Inc. UBS Financial Services Inc. may provide copies
of all statements and confirmations concerning each
Collateral Account to UBS Bank USA at such times and
in such manner as UBS Bank USA may request and may
share with UBS Bank USA any and all information
regarding the Borrower and the Borrower’s accounts
with UBS Financial Services Inc.

 

3

 

IN WITNESS WHEREOF, the undersigned (“Borrower”) has signed this Agreement, or has caused this
Agreement to be signed in its name by its duly authorized representatives, as of the date indicated
below.

DATE: February 16, 2009

Name of Borrower: ABERCROMBIE & FITCH MGMT CO ATTN Scott Lipesky ASSISTANT TREASURER

	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Everett Gallagher
	 	 	 	Title:
	 	Vice President
	 

	 	 
	 	 	 	 	 	 
	 

	 	(Signature of Authorized Signatory of Borrower)*
	 	 	 	 	 	(Title of Authorized Signatory of Borrower)
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Scott Lipesky
	 	 	 	Title:
	 	Asst. Treasurer
	 

	 	 
	 	 	 	 	 	 
	 

	 	(Signature of Authorized Signatory of Borrower)*
	 	 	 	 	 	(Title of Authorized Signatory of Borrower)

The authorized signatory of the Borrower must be one of the Authorized Persons designated on the
applicable UBS Bank USA supplemental form executed by the Borrower (e.g., the Supplemental
Corporate Resolution Form (HP Form))

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]